Linaclotide Capsules 145 Mcg

Linalotide activates the GC-C receptor by specifically binding to the surface epithelial cells of the small and large gut. GC-C receptor is a transmembrane protein widely distributed on the surface of mucosal epithelial cells in the small and large gut. When linaclotide binds to the GC-C receptor, it triggers a conformational change in the receptor, thereby activating its intrinsic guanylate cyclase activity. This process can catalyze the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP), thereby significantly increasing the concentration of intracellular and extracellular cGMP. CGMP, as an important second messenger, plays multiple biological functions in cells, and linaclotide exerts its pharmacological impressions by regulating the level of cGMP.

The increase in intracellular cGMP concentration activates cGMP dependent protein kinase II (PKG II). After PKG II is activated, it phosphorylates a series of downstream target proteins, including cystic fibrosis transmembrane regulator (CFTR). CFTR is a chloride channel protein that opens after phosphorylation, allowing chloride ions and bicarbonate to enter the intestinal lumen through the CFTR channel. This process triggers a change in intestinal osmotic pressure. Due to the increase in chloride ion and bicarbonate concentration in the intestinal lumen, the osmotic pressure in the intestinal lumen rises, causing water to be passively excreted from cells and blood vessels into the intestinal lumen, thereby softening feces and increasing their volume. This mechanism has a direct impression on improving astriction symptoms, significantly increasing the frequency of defecation and the softness of feces in sufferer, making it easier for dry and hard feces to be excreted from the body.

In addition to increasing intestinal fluid secretion, linaclotide also regulates intestinal nerve activity through an increase in extracellular cGMP concentration. Extracellular cGMP can act on intestinal nerve endings, reducing the sensitivity of sore transmitting nerve endings and decreasing the transmission of sore signals. Specifically, cGMP can inhibit the release of neurotransmitters such as substance P and calcitonin gene-related peptides, which play an important role in the transmission of sore signals. By inhibiting their release, cGMP reduces neural excitability and conduction velocity, thereby alleviating abdominal sore caused by IBS-C. In addition, cGMP can regulate the contraction activity of intestinal smooth muscles, making intestinal movment more coordinated, reducing intestinal spasms and abnormal contractions, and further improving sufferer' abdominal discomfort symptoms.

Linalotide further promotes intestinal peritalsis by increasing intestinal fluid secretion and regulating intestinal nerve activity. The increase in secretion of intestinal fluid makes the intestinal contents more lubricating, reduces the resistance of the gut to the contents, and makes it easier for feces to move within the gut. The regulation of intestinal nerve activity makes the contraction of intestinal smooth muscle more coordinated and powerful, enhancing the propulsive movment of the gut. The specific manifestation is an increase in the frequency and amplitude of intestinal peristaltic waves, which accelerates intestinal transport speed. This mechanism helps to shorten the residence time of food in the gut, reduce water absorption, and further improve astriction symptoms. At the same time, normal intestinal peritalsis can promote the expulsion of gas from the guts and alleviate discomfort such as bloating.

Linaclotide capsules 145 mcg is rapidly degraded in the gastrointestinal tract, and its absorption into the bloodstream is extremely low. This characteristic results in fewer systemic side impressions and higher safety of Delinaritide. Due to the fact that drugs mainly function in the gut, they do not have significant impressions on other organs throughout the body, reducing the risk of adverse reactions during the medication process for sufferer. For example, compared to some systemic laxatives, linaclotide does not cause serious adverse reactions such as electrolyte imbalance and intestinal dysfunction, making it more suitable for long-term use.

Linalotide not only promotes intestinal peritalsis and increases intestinal fluid secretion, but also has visceral analgesic impressions. By reducing the sensitivity of sore transmission to nerve endings, linaclotide can alleviate visceral sore caused by IBS-C, inflammatory bowel ailment, and other conditions. In sufferer with inflammatory bowel ailments such as Crohn's ailment and ulcerative colitis, intestinal inflammation can lead to increased sensitivity of intestinal nerve endings, resulting in discomfort symptoms such as abdominal sore. Linaclotide capsules 145 mcg can alleviate abdominal sore symptoms in sufferers by regulating intestinal nerve activity, reducing sore signal transmission caused by inflammation. In addition, for some sufferers with functional abdominal sore syndrome, linaclotide may also have a certain therapeutic impression.

Although the main mechanism of action of linaclotide is not to directly regulate the gut microbiota, it helps to restore normal intestinal peritalsis and defecation function in the process of improving astriction symptoms, thereby indirectly improving the balance of gut microbiota. A healthy gut environment helps maintain the diversity of gut microbiota, reduce the growth of harmful bacteria, and promote the proliferation of beneficial bacteria. When intestinal peritalsis is normal and bowel movments are smooth, food residues can be promptly excreted from the body, reducing the residence time of harmful substances in the gut and providing a favorable environment for the growth of beneficial bacteria. At the same time, the increased secretion of linaclotide in intestinal fluid can also provide suitable living conditions for the gut microbiota and promote the balance of the gut microbiota.